Central Nervous System
Bristol Myers Squibb acquires Karuna Therapeutics for $14bn
Bristol Myers Squibb (BMS) has concluded the acquisition of biopharmaceutical company Karuna Therapeutics for $14bn in cash. The transaction was finalised…
AbCellera and Biogen link on neurological antibody therapy
AbCellera has entered a partnership with Biogen to discover therapeutic antibodies for neurological ailments. The companies will execute the discovery…
Boehringer and Sosei Heptares partner on schizophrenia treatment
Boehringer Ingelheim has entered a deal with Sosei Heptares to develop a new class of treatments for all schizophrenia symptoms.…
Amylyx considers scrapping ALS drug following Phase III flop
Amylyx Pharmaceuticals’s Phase III trial for amyotrophic lateral sclerosis (ALS) Relyvrio has failed to meet any of its endpoints. Following…
MHRA approves Marinus’ ganaxolone for CDKL5 deficiency disorder
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Marinus Pharmaceuticals Emerald’s ganaxolone, marketed as Ztalmy, an anti-seizure…
Minerva hit with FDA rejection for schizophrenia symptom drug
A potential landmark year for schizophrenia treatments has got off to a rocky start, after the US Food and Drug…
Amneal signs agreement with Zambon for Parkinson’s disease therapy
Amneal Pharmaceuticals has signed an exclusive licensing agreement with Zambon Biotech, granting the latter rights to commercialise IPX203 for the…
Sudo secures additional funds to advance TYK2 inhibitors to clinic
Sudo Biosciences has secured an additional $30m in its second round of Series B funding to progress the development of…
J&J touts success of nipocalimab in two rare disease trials
Johnson & Johnson (J&J) has announced positive topline results for nipocalimab in two rare disease indications - generalised myasthenia gravis…
Defender’s plans for motion sickness nasal gel stop with FDA rejection
The FDA has decided to not approve Defender Pharmaceuticals’ intranasal scopolamine candidate for motion sickness, issuing a complete response letter…